← Compound index
COMPOUND RECORD / STAMAKORT

StamakortСтамакорт

A peptide mixture extracted from the stomach lining of young cattle or pigs, studied in a Russian gastric-symptom report.

Source linked

What the studies found

Comparison in people · 2011

Stamakort: institute clinical report (commercially hosted translation)

Fasting total gastric acidity
37.1 ± 1.8 mmol/L with Stamakort versus 31.4 ± 2.4 with usual care. Pretreatment values were 22.6 ± 1.7 and 24.2 ± 2.1, respectively.Table 2 marks p < 0.05 versus usual care.
Free hydrochloric acid
19.2 ± 1.5 versus 15.9 ± 1.3 mmol/L after treatment.Both arms are marked against baseline. No between-group significance mark is printed.

Fasting total gastric acidity was 37.1 mmol/L after Stamakort plus conventional therapy versus 31.4 mmol/L with conventional therapy alone.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls

Design 47 adults with chronic gastritis, 30 receiving adjunctive Stamakort and 17 receiving conventional therapy. The report describes random assignment without a method. It lists one or two 10 mg capsules orally three times daily before meals for 30 days (30–60 mg/day).

Important limitations

  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated. Random allocation is asserted without a method or concealment details; background therapy and surrogate outcomes limit interpretation. Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
  • The report gives no masking, prespecified clinical endpoint or systematic harms assessment.

Institute-attributed report, 2011; commercially hosted brochure pp. 56–57 · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Stamakort

Identity / background source ↗

Research background

Stamakort is a gastric tissue peptide preparation. A Medical Center report described adjunctive use in 47 adults with chronic gastritis.

Compound class
Archival preparation lead
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls

Study methods

Small adjunctive comparison; signed original, allocation and reporting require verification

Independent replication

New citations are not automatically independent replication; shared programs and translated reports require cohort checks

Source access

New indexed primary abstracts and/or report reproductions linked; review depth shown per source

Safety evidence

Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2011

Stamakort: institute clinical report (commercially hosted translation)

Fasting total gastric acidity was 37.1 mmol/L after Stamakort plus conventional therapy versus 31.4 mmol/L with conventional therapy alone.

Fasting total gastric acidity · 37.1 ± 1.8 mmol/L with Stamakort versus 31.4 ± 2.4 with usual care. Pretreatment values were 22.6 ± 1.7 and 24.2 ± 2.1, respectively. · Table 2 marks p < 0.05 versus usual care.

Study notes and original source
2011Human comparative studyFull text available

Stamakort: institute clinical report (commercially hosted translation)

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

Format: PDF · Reviewed: Report reproduction reviewed

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 56–57

Fasting total gastric acidity was 37.1 mmol/L after Stamakort plus conventional therapy versus 31.4 mmol/L with conventional therapy alone.

Results and tables

Reported findings and study design

47 adults with chronic gastritis, 30 receiving adjunctive Stamakort and 17 receiving conventional therapy. The report describes random assignment without a method. It lists one or two 10 mg capsules orally three times daily before meals for 30 days (30–60 mg/day).

Population or model 47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls

Results · Russian Medical Center report, methods and Tables 1–2, PDF pages 69–70
MeasureResultComparison, timing and statistics
Fasting total gastric acidity37.1 ± 1.8 mmol/L with Stamakort versus 31.4 ± 2.4 with usual care. Pretreatment values were 22.6 ± 1.7 and 24.2 ± 2.1, respectively.Table 2 marks p < 0.05 versus usual care.
Free hydrochloric acid19.2 ± 1.5 versus 15.9 ± 1.3 mmol/L after treatment.Both arms are marked against baseline. No between-group significance mark is printed.

The report gives no masking, prespecified clinical endpoint or systematic harms assessment.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls
Source reviewed
Russian Medical Center report, methods and Tables 1–2, PDF pages 69–70.
Study limitations
  • Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
  • Random allocation is asserted without a method or concealment details; background therapy and surrogate outcomes limit interpretation.
  • Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗